KMCRIC

Can acupuncture combined with SSRIs improve clinical symptoms and quality of life in patients with depression? Secondary outcomes of a pragmatic randomized controlled trial.

Zhao B, Li Z, Wang Y, Ma X, Wang X, Wang X, Liang Y, Yang X, Sun Y, Song M, Guo T, Bao T, Fei Y.

Complement Ther Med.

2019

45

295-302.

10.1016/j.ctim.2019.03.015.

31331577

http://www.ncbi.nlm.nih.gov/pubmed/31331577

Acupuncture Points
Acupuncture Therapy/methods
Adult
China
Combined Modality Therapy/methods
Depression/drug therapy*
Depression/therapy*
Depressive Disorder/drug therapy*
Depressive Disorder/therapy*
Electroacupuncture/methods
Female
Humans
Male
Psychiatric Status Rating Scales
Quality of Life
Serotonin Uptake Inhibitors/therapeutic use*
Treatment Outcome

Acupuncture; Clinical symptoms; Depression; Quality of life; SSRIs

KMCRIC 비평 보기 +

OBJECTIVES:
To explore the effects of acupuncture (manual acupuncture or electroacupuncture) combined with SSRIs for moderate to severe depression improving major clinical symptoms and life quality of the patients on secondary outcomes.

DESIGN:
Pragmatic, parallel, randomized controlled trial.

SETTING:
6 hospitals in China.

INTERVENTIONS:
6 weeks of manual acupuncture (MA)+selective serotonin reuptake inhibitors (SSRIs), electroacupuncture (EA)+SSRIs, and SSRIs alone.

MAIN OUTCOME MEASURES:
The primary outcome was response rate of 17-item Hamilton Depression Scale (HAMD-17) total score at 6th week. The secondary outcomes reported in this analysis were HAMD-17 factor scores at 1st, 2nd, 4th, 6th, 10th week and WHO Quality of Life-BREF (WHOQOL-BREF) scores at 6th week.

RESULTS:
477 patients were randomly assigned into MA + SSRIs (n = 161), EA + SSRIs (n = 160), or SSRIs alone (n = 156) groups. For HAMD-17 (at 6th week), the MA + SSRIs group was significantly better than the SSRIs alone group in retardation factor (p = 0.008), while the EA+SSRIs group was significantly better than the SSRIs alone group in anxiety/somatization factor (p<0.001) and sleep disturbance factor (p = 0.002). For WHOQOL-BREF (at 6th week), the EA + SSRIs group, compared with the SSRIs alone group, produced a more significant improvement in the overall quality of life, general health, physical health, and psychological health (p<0.05). While, the MA + SSRIs group, compared to the SSRIs alone group, showed significant advantage only in psychological health (p = 0.023).

CONCLUSIONS:
Either MA or EA combined SSRIs treatment could improve symptoms and quality of life for patients with moderate to severe depression. The main limitation of this trial was not using a sham control therefore the placebo effect could not be excluded.

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

영어